Dr. Somani is the senior-most medical oncologist in Rajasthan, and he is the head of the medical oncology department at HCG Cancer Centre, Jaipur.
With more than 23 years’ experience, he is an expert in treating patients with immunotherapy & targeted therapies.
His primary areas of interest are cancers of the breast & head and neck region.
Dr. Somani also has vast experience in managing leukaemias and lymphomas.
Rajasthan Medical Council has recognised his extraordinary performance in Medical Oncology, his meritorious and dedicated services and his humanitarian approach in 2017.
He was also the recipient of the “Best Oncologist of Jaipur” award based on a Patient Feedback survey by Innate Group of Company in 2014.
In 2014, he was honoured with the “ICON of Rajasthan” award by India Today Group.
He was also a recipient of other prestigious awards, such as the Young JMA Achievement Award and Young MPS Achievement Award.
Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy. The South Asian Journal of Cancer Published Volume 6 Issue,1 January- March 2017
Nimotuzumab with Concurrent Chemo-Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). Journal of Cancer Therapy, 2015, 6, 356-361 Published Online April 2015.
Myelodysplastic Syndromes: A Challenging Disease for Patients and Physicians (JAPI/Feb 2012, VOL. 60)
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, Placebo-controlled study (Published in The Lancet Journal Oncology 2012; 13: 154–62)
Sequential therapy (triple drug-based induction chemotherapy followed by concurrent chemoradiotherapy) in locally advanced inoperable head and neck cancer patients – Single institute experience ( Nov 2011)
Intravenous Aflibercept in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites: Key Efficacy and Safety Results of Phase II, Randomised, Double-Blind, Placebo-Controlled Study, ESGO2009, V3 (24 June-09).
Modified BEACOPP regime as a cost-effective therapy for unfavourable Hodgkin’s disease in underprivileged countries” (Shantanu Sharma, Naresh Somani, S.C. Pande, Nidhi Patni). Presented at 38th Annual Conference of the International Society of Paediatric Oncology (SIOP), Geneva, Switzerland, Sept. 2006 and published in “Pediatric Blood & Cancer” Volume 47, Issue 4, Oct. 1, 2006, PJ.017, ISSN 1545-5009.
A pilot study of BEACOPP (Basic & “modified escalated”) chemotherapy with or without involved-field radiotherapy in Hodgkin’s disease: A cost-effective & risk-stratified protocol in Indian context” (Published in Indian Journal of Medical & Paediatric Oncology – ISSN 0971-5851).
Activity of specific inhibitor of epidermal growth factor receptor (Gefitinib) in refractory Non-Small-Cell Cancer (NSCLC) – Published in Current Medical Trends – ISSN 0972-3390.
Review article: systemic treatment of primary breast cancer JAPI, Vol. No. 49, April 2001 (ISSN-0004-5772).
Review article: an overview of the management of primary pulmonary lymphoma, Current Medical Trends (ISSN 0972-3390).
HCG - The Specialist in Cancer Care, India’s largest provider of cancer care, is at the forefront of the battle against cancer. Through its network of 24 comprehensive cancer centers, spread across India, HCG has brought advanced cancer care to the doorstep of millions of people.